<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054998</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0435</org_study_id>
    <secondary_id>NCI-2019-02459</secondary_id>
    <secondary_id>2017-0435</secondary_id>
    <nct_id>NCT05054998</nct_id>
  </id_info>
  <brief_title>Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases</brief_title>
  <official_title>A Pilot Study of Dual Time Point FDG PET MR Imaging Optimization for the Evaluation of Brain Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IV trial studies how well delaying positron emission tomography (PET)/magnetic&#xD;
      resonance imaging (MRI) scan after injection of fluorodeoxyglucose (FDG) can improve the&#xD;
      imaging of patients with cancer that has spread to brain (brain metastases). FDG is a type of&#xD;
      imaging agent that doctors use to help &quot;see&quot; the images on a scan more clearly. Delaying&#xD;
      PET/MRI scan after injecting FDG may improve how well doctors can tell the difference between&#xD;
      healthy and unhealthy tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the optimal fludeoxyglucose F-18 (fluorodeoxyglucose) positron emission&#xD;
      tomography (FDG PET) imaging time post radiotracer administration that maximizes separation&#xD;
      of activity between lesion and non-lesional parenchyma (measured as lesion/background [L/B]&#xD;
      ratio) in patients with brain metastasis.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To identify genotypic factors in FDG tumor metabolism derived from metrics, including&#xD;
      maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion&#xD;
      glycolysis (TLG), mean tumor volume (MTV), and L/B ratio.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To identify patterns of metabolism derived from metrics, such as SUVmax, SUVmean, TLG,&#xD;
      MTV, and L/B ratio, and magnetic resonance imaging metrics, such as regional perfusion&#xD;
      abnormalities, apparent diffusion coefficient values, fractional diffusivity measures, and&#xD;
      magnetic resonance spectroscopic finding.&#xD;
&#xD;
      II. To identify if post treatment changes in lesion metabolism from baseline correlate with&#xD;
      treatment success.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive fludeoxyglucose F-18 intravenously (IV) over approximately 1 minute and&#xD;
      undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18,&#xD;
      patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks&#xD;
      before scheduled surgery and within 4-6 weeks after radiation treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess the optimal fludeoxyglucose F-18 (fluorodeoxyglucose) positron emission tomography (FDG PET) imaging time post radiotracer administration that maximizes separation of activity between lesion and non-lesional parenchyma</measure>
    <time_frame>through study completion, an average of a year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <condition>Metastatic Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (fludeoxyglucose F-18, PET/MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludeoxyglucose F-18 IV over approximately 1 minute and undergo a PET/MRI scan over 70 minutes. Within 5 hours of receiving fludeoxyglucose F-18, patients undergo a repeat PET/MRI scan over 30 minutes. Scans take place within 2 weeks before scheduled surgery and within 4-6 weeks after radiation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (fludeoxyglucose F-18, PET/MRI)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>Fludeoxyglucose (18F)</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (fludeoxyglucose F-18, PET/MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (fludeoxyglucose F-18, PET/MRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre-treatment adult patients with any solid organ metastasis and at least three&#xD;
             intraaxial brain metastases including at least one enhancing &gt; 10 mm lesion&#xD;
&#xD;
          -  Rim or solid enhancing lesion(s) WITH a history of non-central nervous system (CNS)&#xD;
             pathologic proven metastatic disease will be considered as a consensus between the&#xD;
             referring radiation oncologist or neurosurgeon and a neuroradiology&#xD;
&#xD;
          -  Planned surgery or radiation to the metastases&#xD;
&#xD;
          -  Ability to undergo PET magnetic resonance (MR) examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to FDG or gadolinium based contrast agents&#xD;
&#xD;
          -  History of impaired renal function (glomerular filtration rate [GFR] &lt; 30)&#xD;
&#xD;
          -  Pregnant women are excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason M Johnson</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Johnson</last_name>
    <phone>713-792-8443</phone>
    <email>jcjohnson@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Johnson</last_name>
      <phone>713-792-8443</phone>
    </contact>
    <investigator>
      <last_name>Jason Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

